HIGH-DOSE RECOMBINANT INTERLEUKIN-2 IN ADVANCED CUTANEOUS T-CELL LYMPHOMA

被引:43
作者
MAROLLEAU, JP
BACCARD, M
FLAGEUL, B
RYBOJAD, M
LAROCHE, L
VEROLA, O
BRANDELY, M
MOREL, P
GISSELBRECHT, C
机构
[1] HOP ST LOUIS,DEPT DERMATOL PROF MOREL,F-75010 PARIS,FRANCE
[2] HOP ST LOUIS,DEPT DERMATOL PROF DUBERTRET,F-75010 PARIS,FRANCE
[3] HOP ST LOUIS,DEPT ANATOMOPATHOL,F-75010 PARIS,FRANCE
[4] HOP AVICENNE,DEPT DERMATOL,F-93009 BOBIGNY,FRANCE
[5] ROUSSEL UCLAF LAB,ROMAINVILLE,FRANCE
关键词
D O I
10.1001/archderm.131.5.574
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and Design: Treatment of cutaneous T-cell lymphoma is still a difficult challenge, once the usual therapies (topical chemotherapy, phototherapy, radiation therapy, and chemotherapy) have proved to be unsuccessful. New therapies, mostly immunotherapies, are currently under investigation. The use of recombinant interleukin-2 has already been evaluated in hematopoietic malignancies. We decided to treat patients with advanced cutaneous T-cell lymphoma relapsing or progressing in spite of the usual treatments with high-dose recombinant interleukin-2. Seven patients (three with mycosis fungoides, three with Sezary syndrome, and one with nonepidermotropic large-cell cutaneous lymphoma) were included in this open study. They were scheduled to receive recombinant interleukin-2 at a dose of Z0x10(6) IU/m(2) per day, administered by continuous infusion during three fortnightly. induction cycles and five monthly consolidation cycles. Results: Three complete responses (two responses to mycosis fungoides; one response to large-cell lymphoma) and two partial responses were obtained. The clinical response appeared after the first cycle of treatment in the good responders. The complete responses are still ongoing 33, 28, and 6 months after completion of recombinant interleukin-2 therapy and without any further treatment. Sequential immunophenotypic studies showed an increase of the CD1(+) cells in the dermal infiltrates. No significant modification of natural killer or cytotoxic T cells could be seen. Conclusions: Despite our low number of cases, our results clearly show that some advanced cutaneous T-cell lymphomas can benefit from high-dose recombinant interleukin-2 therapy. Further studies are necessary to determine the exact place of recombinant interleukin-2 in the therapeutic arsenal of cutaneous T-cell lymphoma.
引用
收藏
页码:574 / 579
页数:6
相关论文
共 22 条
[1]   PHASE-II TRIAL OF OUTPATIENT INTERLEUKIN-2 IN MALIGNANT-LYMPHOMA, CHRONIC LYMPHOCYTIC-LEUKEMIA, AND SELECTED SOLID TUMORS [J].
ALLISON, MAK ;
JONES, SE ;
MCGUFFEY, P .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (01) :75-80
[2]  
BUNN PA, 1979, CANCER TREAT REP, V63, P725
[3]   INTERLEUKIN-7 IS A GROWTH-FACTOR FOR SEZARY LYMPHOMA-CELLS [J].
DALLOUL, A ;
LAROCHE, L ;
BAGOT, M ;
MOSSALAYI, MD ;
FOURCADE, C ;
THACKER, DJ ;
HOGGE, DE ;
MERLEBERAL, H ;
DEBRE, P ;
SCHMITT, C .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (03) :1054-1060
[4]  
FOA R, 1991, BRIT J HAEMATOL, V77, P491
[5]  
GISSELBRECHT C, 1994, BLOOD, V83, P2081
[6]  
HESSE S, 1991, MAR M DERM ASS PAR
[7]   THERAPEUTIC ALTERNATIVES IN CUTANEOUS T-CELL LYMPHOMA [J].
HOLLOWAY, KB ;
FLOWERS, FP ;
RAMOSCARO, FA .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1992, 27 (03) :367-381
[8]   PHASE-II STUDY OF RECOMBINANT HUMAN INTERFERON-GAMMA FOR TREATMENT OF CUTANEOUS T-CELL LYMPHOMA [J].
KAPLAN, EH ;
ROSEN, ST ;
NORRIS, DB ;
ROENIGK, HH ;
SAKS, SR ;
BUNN, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (03) :208-212
[9]   A RANDOMIZED TRIAL COMPARING COMBINATION ELECTRON-BEAM RADIATION AND CHEMOTHERAPY WITH TOPICAL THERAPY IN THE INITIAL TREATMENT OF MYCOSIS-FUNGOIDES [J].
KAYE, FJ ;
BUNN, PA ;
STEINBERG, SM ;
STOCKER, JL ;
IHDE, DC ;
FISCHMANN, AB ;
GLATSTEIN, EJ ;
SCHECHTER, GP ;
PHELPS, RM ;
FOSS, FM ;
PARLETTE, HL ;
ANDERSON, MJ ;
SAUSVILLE, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (26) :1784-1790
[10]   MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME - A REVIEW OF PATHOGENESIS, DIAGNOSIS, AND THERAPY [J].
KUZEL, TM ;
ROENIGK, HH ;
ROSEN, ST .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (07) :1298-1313